HNRNPA2B1 Stabilizes NFATC3 Levels to Potentiate Its Combined Actions with FOSL1 to Mediate Vasculogenic Mimicry in GBM Cells

Overview

Journal Cell Biol Toxicol

Publisher Springer

Specialties Cell Biology
Toxicology

Date 2024 Jun 11

PMID 38862832

Authors

Hanting Wang

Yiwen Shi

Xinxin Zhou

Lu Zhang

Aodan Yang

Dabo Zhou

Teng Ma

Affiliations

Soon will be listed here.

Abstract

Background: Vasculogenic mimicry (VM) is an enigmatic physiological feature that influences blood supply within glioblastoma (GBM) tumors for their sustained growth. Previous studies identify NFATC3, FOSL1 and HNRNPA2B1 as significant mediators of VEGFR2, a key player in vasculogenesis, and their molecular relationships may be crucial for VM in GBM.

Aims: The aim of this study was to understand how NFATC3, FOSL1 and HNRNPA2B1 collectively influence VM in GBM.

Methods: We have investigated the underlying gene regulatory mechanisms for VM in GBM cell lines U251 and U373 in vitro and in vivo. In vitro cell-based assays were performed to explore the role of NFATC3, FOSL1 and HNRNPA2B1 in GBM cell proliferation, VM and migration, in the context of RNA interference (RNAi)-mediated knockdown alongside corresponding controls. Western blotting and qRT-PCR assays were used to examine VEGFR2 expression levels. CO-IP was employed to detect protein-protein interactions, ChIP was used to detect DNA-protein complexes, and RIP was used to detect RNA-protein complexes. Histochemical staining was used to detect VM tube formation in vivo.

Results: Focusing on NFATC3, FOSL1 and HNRNPA2B1, we found each was significantly upregulated in GBM and positively correlated with VM-like cellular behaviors in U251 and U373 cell lines. Knockdown of NFATC3, FOSL1 or HNRNPA2B1 each resulted in decreased levels of VEGFR2, a key growth factor gene that drives VM, as well as the inhibition of proliferation, cell migration and extracorporeal VM activity. Chromatin immunoprecipitation (ChIP) studies and luciferase reporter gene assays revealed that NFATC3 binds to the promoter region of VEGFR2 to enhance VEGFR2 gene expression. Notably, FOSL1 interacts with NFATC3 as a co-factor to potentiate the DNA-binding capacity of NFATC3, resulting in enhanced VM-like cellular behaviors. Also, level of NFATC3 protein in cells was enhanced through HNRNPA2B1 binding of NFATC3 mRNA. Furthermore, RNAi-mediated silencing of NFATC3, FOSL1 and HNRNPA2B1 in GBM cells reduced their capacity for tumor formation and VM-like behaviors in vivo.

Conclusion: Taken together, our findings identify NFATC3 as an important mediator of GBM tumor growth through its molecular and epistatic interactions with HNRNPA2B1 and FOSL1 to influence VEGFR2 expression and VM-like cellular behaviors.

References

Bengsch B, Wherry E . The importance of cooperation: partnerless NFAT induces T cell exhaustion. Immunity. 2015; 42(2):203-205. DOI: 10.1016/j.immuni.2015.01.023. View

Batchelor T, Duda D, Tomaso E, Ancukiewicz M, Plotkin S, Gerstner E . Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010; 28(17):2817-23. PMC: 2903316. DOI: 10.1200/JCO.2009.26.3988. View

Urso K, Fernandez A, Velasco P, Cotrina J, de Andres B, Sanchez-Gomez P . NFATc3 controls tumour growth by regulating proliferation and migration of human astroglioma cells. Sci Rep. 2019; 9(1):9361. PMC: 6597574. DOI: 10.1038/s41598-019-45731-w. View

Sobolev V, Khashukoeva A, Evina O, Geppe N, Chebysheva S, Korsunskaya I . Role of the Transcription Factor FOSL1 in Organ Development and Tumorigenesis. Int J Mol Sci. 2022; 23(3). PMC: 8835756. DOI: 10.3390/ijms23031521. View

Yin J, Ge X, Shi Z, Yu C, Lu C, Wei Y . Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p. Theranostics. 2021; 11(4):1763-1779. PMC: 7778586. DOI: 10.7150/thno.47057. View

Zhao Z, Zhang K, Wang Q, Li G, Zeng F, Zhang Y . Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients. Genomics Proteomics Bioinformatics. 2021; 19(1):1-12. PMC: 8498921. DOI: 10.1016/j.gpb.2020.10.005. View

Qin J, Nag S, Wang W, Zhou J, Zhang W, Wang H . NFAT as cancer target: mission possible?. Biochim Biophys Acta. 2014; 1846(2):297-311. PMC: 4710172. DOI: 10.1016/j.bbcan.2014.07.009. View

Liu X, Zhang Q, Mu Y, Zhang X, Sai K, Pang J . Clinical significance of vasculogenic mimicry in human gliomas. J Neurooncol. 2011; 105(2):173-9. PMC: 3198193. DOI: 10.1007/s11060-011-0578-5. View

Wu H, Yang S, Weng H, Chen Q, Zhao X, Fu W . Autophagy-induced KDR/VEGFR-2 activation promotes the formation of vasculogenic mimicry by glioma stem cells. Autophagy. 2017; 13(9):1528-1542. PMC: 5612353. DOI: 10.1080/15548627.2017.1336277. View

10.

Huelga S, Vu A, Arnold J, Liang T, Liu P, Yan B . Integrative genome-wide analysis reveals cooperative regulation of alternative splicing by hnRNP proteins. Cell Rep. 2012; 1(2):167-78. PMC: 3345519. DOI: 10.1016/j.celrep.2012.02.001. View

11.

Graef I, Chen F, Chen L, Kuo A, Crabtree G . Signals transduced by Ca(2+)/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell. 2001; 105(7):863-75. DOI: 10.1016/s0092-8674(01)00396-8. View

12.

Yu P, Kang A, Jing L, Wang Y . Long non-coding RNA CACNA1G-AS1 promotes cell migration, invasion and epithelial-mesenchymal transition by HNRNPA2B1 in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2018; 22(4):993-1002. DOI: 10.26355/eurrev_201802_14381. View

13.

Azzi J, Sayegh M, Mallat S . Calcineurin inhibitors: 40 years later, can't live without . J Immunol. 2013; 191(12):5785-91. DOI: 10.4049/jimmunol.1390055. View

14.

Buccarelli M, Castellani G, Ricci-Vitiani L . Glioblastoma-Specific Strategies of Vascularization: Implications in Anti-Angiogenic Therapy Resistance. J Pers Med. 2022; 12(10). PMC: 9604754. DOI: 10.3390/jpm12101625. View

15.

LaPointe S, Perry A, Butowski N . Primary brain tumours in adults. Lancet. 2018; 392(10145):432-446. DOI: 10.1016/S0140-6736(18)30990-5. View

16.

Lofgren D, Valachis A, Olivecrona M . Risk for morbidity and mortality after neurosurgery in older patients with high grade gliomas - a retrospective population based study. BMC Geriatr. 2022; 22(1):805. PMC: 9575213. DOI: 10.1186/s12877-022-03478-6. View

17.

Goshima T, Habara M, Maeda K, Hanaki S, Kato Y, Shimada M . Calcineurin regulates cyclin D1 stability through dephosphorylation at T286. Sci Rep. 2019; 9(1):12779. PMC: 6726757. DOI: 10.1038/s41598-019-48976-7. View

18.

Ning H, Zhang L, Zhu B, Zhou X, Zhang T, Ma T . TARBP2-stablized SNHG7 regulates blood-brain barrier permeability by acting as a competing endogenous RNA to miR-17-5p/NFATC3 in Aβ-microenvironment. Cell Death Dis. 2022; 13(5):457. PMC: 9106673. DOI: 10.1038/s41419-022-04920-8. View

19.

Luo Q, Wang J, Zhao W, Peng Z, Liu X, Li B . Vasculogenic mimicry in carcinogenesis and clinical applications. J Hematol Oncol. 2020; 13(1):19. PMC: 7071697. DOI: 10.1186/s13045-020-00858-6. View

20.

Kamoun W, Ley C, Farrar C, Duyverman A, Lahdenranta J, Lacorre D . Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol. 2009; 27(15):2542-52. PMC: 2739611. DOI: 10.1200/JCO.2008.19.9356. View